Accuray Incorporated (ARAY)
Stock Price Chart
Key Info
| Market Cap | 282.72M |
| Revenue (ttm) | 382.93M |
| Net Income (ttm) | 3.83M |
| Shares Out | 91.20M |
| EPS (ttm) | 0.04 |
| PE Ratio | 77.50 |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Oct 23, 2020 |
| Last Price | $3.10 |
| Previous Close | $3.13 |
| Change ($) | -0.03 |
| Change (%) | -0.96% |
| Day's Open | 3.10 |
| Day's Range | 3.08 - 3.14 |
| Day's Volume | 445,888 |
| 52-Week Range | 1.33 - 4.68 |
More Stats
| Market Cap | 282.72M |
| Enterprise Value | 394.52M |
| Earnings Date (est) | Oct 29, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 91.20M |
| Float | 87.05M |
| EPS (basic) | 0.04 |
| EPS (diluted) | 0.04 |
| FCF / Share | -0.06 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | 1.29% |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 4.35M |
| Short Ratio | 5.88 |
| Short % of Float | 4.99% |
| Beta | 2.03 |
| PE Ratio | 77.50 |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 0.74 |
| PB Ratio | 4.44 |
| Revenue | 382.93M |
| Operating Income | 12.54M |
| Net Income | 3.83M |
| Free Cash Flow | -5.03M |
| Net Cash | -111.79M |
| Net Cash / Share | -1.23 |
| Gross Margin | 39.10% |
| Operating Margin | 3.27% |
| Profit Margin | 1.00% |
| FCF Margin | -1.31% |
| ROA | 1.69% |
| ROE | 6.74% |
| ROIC | 1.60% |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 383 | 419 | 405 | 383 | 399 | 380 | 369 | 316 | 409 | 222 |
| Revenue Growth | -8.56% | 3.43% | 5.6% | -3.86% | 5% | 2.81% | 16.91% | -22.79% | 84.1% | - |
| Gross Profit | 150 | 163 | 162 | 141 | 159 | 145 | 143 | 97.64 | 137 | 107 |
| Operating Income | 12.54 | 0.58 | -3.80 | -9.82 | -4.87 | -19.17 | -18.14 | -92.86 | -56.23 | -27.83 |
| Net Income | 3.83 | -16.43 | -23.90 | -29.58 | -25.50 | -40.21 | -35.45 | -103 | -72.04 | -26.68 |
| Shares Outstanding | 89.87 | 87.47 | 84.89 | 82.50 | 80.51 | 78.28 | 75.80 | 73.28 | 70.89 | 60.09 |
| Earnings Per Share | 0.04 | -0.19 | -0.28 | -0.36 | -0.32 | -0.51 | -0.47 | -1.41 | -1.02 | -0.44 |
| Operating Cash Flow | -1.47 | -29.64 | 18.33 | -0.38 | 30.93 | -14.41 | 0.35 | -66.18 | -38.28 | 12.40 |
| Capital Expenditures | -3.56 | -4.31 | -6.28 | -5.03 | -8.07 | -10.45 | -11.93 | -15.13 | -10.77 | -4.02 |
| Free Cash Flow | -5.03 | -33.95 | 12.06 | -5.41 | 22.86 | -24.85 | -11.59 | -81.30 | -49.05 | 8.38 |
| Cash & Equivalents | 110 | 88.18 | 93.53 | 109 | 169 | 148 | 173 | 177 | 145 | 99.08 |
| Total Debt | 222 | 160 | 131 | 165 | 210 | 200 | 196 | 199 | 79.47 | - |
| Net Cash / Debt | -112 | -71.67 | -37.54 | -55.43 | -41.04 | -52.06 | -22.22 | -21.64 | 65.60 | 99.08 |
| Assets | 491 | 438 | 379 | 406 | 469 | 467 | 495 | 476 | 473 | 456 |
| Liabilities | 427 | 388 | 330 | 360 | 409 | 391 | 397 | 369 | 269 | 215 |
| Book Value | 63.64 | 49.87 | 48.63 | 46.53 | 59.66 | 75.78 | 98.55 | 107 | 196 | 230 |
Company Profile
Company Details
| Full Name | Accuray Incorporated |
| Country | United States |
| Employees | 932 |
| CEO | Joshua H. Levine |
Stock Information
| Ticker Symbol | ARAY |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Unique Identifier | NASDAQ: ARAY |
| IPO Date | February 8, 2007 |
Description
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body in the Americas, Europe, the Middle East, India, Japan, Africa, and rest of the Asia Pacific region. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. Its CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of precise, high dose radiation while patients breathe normally. The company also offers the TomoTherapy System, including the Radixact System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. It markets its products in the United States directly, as well as through sales organizations, sales agents, and group purchasing organizations; and directly, as well as through distributors and sales agents in Europe, Asia, and South America to hospitals and stand-alone treatment facilities. The company was incorporated in 1990 and is headquartered in Sunnyvale, California.